Postoperative pain is the unpleasant sensory and emotional experience after surgery, its origin being both the inflammatory reaction induced by the surgical trauma on the abdominal wall and the splanchnic pain induced by the activation of nociceptors of the viscera, which are highly sensitive to distension, ischemia, and inflammation. Nowadays, it is well recognized that there is a close relationship between the gut microbiome and pain perception, and that microbiome is highly affected by both anesthesia and surgical manipulation. Thus, efforts to restore the disturbed microbiome via supplementation with beneficial bacteria, namely probiotics, seem to be effective. In this article, the knowledge gained mainly from experimental research on this topic is analyzed, the concluding message being that each probiotic strain works in its own way towards pain relief.

Recent advances in neuromodulation are opening new pathways for treating chronic pain, with spinal cord stimulation (SCS) poised for substantial transformation in the coming years. Evolving technologies and a deeper understanding of pain mechanisms are driving a move away from traditional, standardized stimulation models toward more precise and personalized interventions. This shift reflects not only technical progress but also a growing emphasis on tailoring treatment to individual patient profiles. Advances in neuromodulation have introduced new stimulation patterns such as high-frequency, burst and dorsal root ganglion stimulation, which developed to address the limitations of conventional tonic SCS, especially declining long-term efficacy and the need for paresthesia. Early studies show promising results for these newer modalities, but findings are inconsistent and long-term data remain limited. In this article, we explore the current landscape of SCS innovation, highlight emerging clinical approaches and discuss the conceptual and technological trends that are likely to redefine the role of neuromodulation in chronic pain management.

Background: Postoperative thrombocytopenia is a frequent finding after cardiac surgery, affecting approximately 10–40% of patients. The early decline in platelet count, typically observed within the first 48–72 h, is usually explained by hemodilution, perioperative platelet consumption, and the inflammatory or mechanical impact of cardiopulmonary bypass (CPB). However, a secondary decrease occurring beyond postoperative day 5 should raise suspicion for more serious causes, the most important being heparin-induced thrombocytopenia (HIT), a rare but potentially life-threatening complication. Objectives: This review aims to outline the characteristic patterns of postoperative thrombocytopenia in cardiac surgery, provide a practical framework for differential diagnosis, and summarize up-to-date evidence on the diagnosis and management of HIT. Methods: A narrative review was conducted through searches in PubMed, Scopus, and Embase up to September 2025. Conclusions: Recognizing platelet count trends early and applying a stepwise diagnostic approach can help distinguish benign postoperative thrombocytopenia from HIT and other critical causes. The combination of clinical assessment using the 4Ts score and appropriate confirmatory testing remains central to accurate diagnosis. Tailoring anticoagulant therapy to individual patient requirements—including surgical procedure, renal and hepatic function, and bleeding risk—is essential for reducing thrombotic events and improving postoperative outcomes.

Post-operative pain is the unpleasant sensory and emotional experience after surgery, its origin being both the inflammatory reaction induced by the surgical trauma on the abdominal wall, and the splanchnic pain, induced by the activation of nociceptors of the viscera, which are highly sensi-tive to distension, ischemia and inflammation. Nowadays, it is well recognized that there is a close relationship between the gut microbiome and pain perception, and that microbiome is highly af-fected by both anaesthesia and surgical manipulation. Thus, efforts to restore the disturbed micro-biome by supplementation with beneficial bacteria, namely probiotics, seems to be effective. In this article the knowledge gained mainly from experimental research on this topic is analyzed, the con-cluding message being that each probiotic strain works in its own way towards pain relief.

Background: Pain is a multifaceted and debilitating symptom in patients with gastrointestinal cancer, especially those undergoing surgical resection followed by chemotherapy. The interplay between inflammatory, neuropathic, and psychosocial components often renders conventional analgesia insufficient. Psychobiotics—probiotic strains with neuroactive properties—have recently emerged as potential modulators of pain perception through neuroimmune and gut–brain axis pathways. Methods: This post hoc analysis is based on the ProDeCa randomized, placebo-controlled trial, which originally aimed to assess the psychotropic effects of a four-strain psychobiotic formulation in postoperative gastrointestinal cancer patients receiving chemotherapy. In the current analysis, we evaluated changes in pain perception among non-depressed and depressed participants, who received either psychobiotics or placebo, along with standard analgesic regimes. Pain was assessed at baseline, after a month of treatment, and at follow-up, 2 months thereafter, using the Short-Form McGill Pain Questionnaire (SF-MPQ), capturing both sensory and affective components, as well as with the Present Pain Intensity and the VAS scores. Results: Psychobiotic-treated participants—particularly the non-depressed ones—exhibited a significant reduction in both quantitative and qualitative pain indices over time compared with placebo-treated ones. Improvements were noted in total pain rating index scores, sensory and affective subscales, and present pain intensity. These effects were sustained up to 2 months after intervention. In contrast, placebo groups demonstrated worsening in pain scores, probably influenced by ongoing chemotherapy and disease progression. The analgesic effect was less pronounced but still observable in the subgroup with symptoms of depression. Conclusions: Adjunctive psychobiotic therapy appears to beneficially modulate pain perception in gastrointestinal oncology patients receiving chemotherapy, with the most pronounced effects being in non-depressed individuals. These findings suggest psychobiotics as a promising non-opioid add-on for comprehensive cancer pain management and support further investigation in larger pain-targeted trials.

Background: The attitudes and beliefs of patients with chronic pain significantly affect their response to treatment. The Survey of Pain Attitudes (SOPA) scale was developed to identify pain-related beliefs. The aim of the present study was to adapt and validate the short version (30 items) of the Survey of Pain Attitudes in 200 Greek patients living with chronic pain, mainly due to rheumatic and musculoskeletal diseases (RMDs). Method: In addition to the SOPA-Brief scale (30 items), the participants completed the Pain Beliefs, Perceptions and Attitudes Inventory (PBAPI) and also the Chronic Pain Coping Inventory (CPCI). Results: Data analysis revealed that the internal reliability coefficient of the scale in the Greek language was Cronbach’s a = 0.773 for the individual items, and for the subscales, it ranged from Cronbach’s a = 0.56 (for the SOPAMedication scale) to Cronbach’s a = 0.78 (for the SOPASolicitude scale). Similarly, the SOPA-Brief subscales in Greek showed positive correlations with subscales of both the PBAPI and the CPCI. Finally, an exploratory factor analysis was performed on the dataset and confirmed the structure of the original scale (Eigenvalues > 1), with 71.54% of variance explained. Conclusions: Overall, the psychometric properties of the short version of the Attitudes Towards Pain Scale (30 items) in Greek show acceptable internal reliability and validity for the scale to be used in daily clinical and research practice.